In 2016, following a comprehensive multistep-evaluation by national and international experts in ICT and E-Health, the Research Council of Norway selected DoMore! as one of three projects to receive funding as part of its ambitious Lighthouse Project scheme. As the name suggests, Lighthouse Projects were intended to be beacons, guiding and inspiring future projects to address large societal challenges using cutting-edge technology. Upon conclusion of the project in 2021, we are proud to have contributed to the digitalization of pathology and paved the way for the transition from digital pathology to in silico pathology, in addition to introducing AI and Deep Learning into tissue diagnostics.
Explore results of the DoMore!-project (2016 - 2021): Results
The DoMore! project is split into 7 work packages defining the steps necessary for completion of the project. Each Work package (WP) has a dedicated team reporting to the project administration. This approach has contributed to the projects success.
Production of images that will be used in methods development (WP-2-6) and in the test and validation studies in WP7.
Click for more details on the Data Production WP
Fully automatisation of the analysis pipeline for the use of deep learning and big data to develop new grading systems for colorectal and lung cancer.
See details of the Histotyping Work Package
Developing reliable, fully automatic methods for tumor delineation and nuclear segmentation in tissue sections.
Click here for more information
Finding biomarkers based on analysis of nuclei in tissue sections. Further developed research tools for practical use in routine pathology.
Read more about the Work Package here
Establishing solutions that ensure efficient data flow of quality-controlled images.
Developing a decision support system for prognostication of cancer patients using machine learning techniques applied to large datasets. Health economy and commercialisation.
Click here for more information on this Work Package
Test and validation studies, scientific publications and dissemination.
The DoMore! project was in 2016 selected as one of the Norwegian Research Council’s Lighthouse projects aiming to solve large societal challenges using cutting-edge technology. Understanding how a tumour will develop is essential for the proper treatment of cancer patients. A range of artificial intelligence products based on the DoMore!-research will be available to assist clinicians in the near future.
Using deep convolutional neural networks has enabled more accurate prognostication of cancer.
Heterogeneity is one of the key research interests for the DoMore!-project.
As the amount of cancer patients rises, we need more advanced tools to give patients more reliable diagnostics and prognostics.
- the final event, in Oslo 24.11.2021
We need better tools to accurately assess the patient's outcome. Many cancer patients receive more treatment than they need. Overtreated patients are susceptible to severe side effects and reduced quality of life. This is a burden to patients and expensive to society. The shortage of pathologists only adds to the increasing difficulty to keep up with patient demand. The manual laboratory procedures needed to render a prognosis are time-consuming and subjective.The DoMore! project provides digital tools, to increase efficiency in pathology and to provide a more accurate prognosis to cancer patients. This will make the process of choice of treatment faster and safer, for both patients and clinicians.
We need better tools to accurately assess the patient's outcome. Many cancer patients receive more treatment than they need.
Overtreated patients are susceptible to severe side effects and reduced quality of life. This is a burden to patients and expensive to society.
The shortage of pathologists only adds to the increasing difficulty to keep up with patient demand. The manual laboratory procedures needed to render a prognosis are time-consuming and subjective.The DoMore! project provides digital tools, to increase efficiency in pathology and to provide a more accurate prognosis to cancer patients. This will make the process of choice of treatment faster and safer, for both patients and clinicians.
The interactive graphics linked above show prostate cancer in 3D and demonstrate heterogeneity as it is observed in sections.
A tumor can contain several regions of different and unevenly distributed aberrations that may or may not lead to cancer. This is called heterogeneity, and is a great challenge for prognosis of cancer. Prognostication and sampling are also challenges being explored in the DoMore! project.
We don't know enough about how to divide between a dangerous and less dangerous tumor. Cancers can follow multiple paths. Predicting the further development of the disease is complicated. Some will progress to metastases and death while others will remain indolent.
The pathologists who are currently doing the work need several years of specialisation. Health systems around the world experience a major shortage of this specialist group. Today´s prognostication is based on subjective assessments. If the conclusion is incorrect, it may cause additional costs, unnecessary side effects and, at worst, the death of the patient.
A single tumour can contain multiple regions of different and unevenly distributed aberrations that might or might not lead to cancer.
We seek a broader understanding of cancer heterogeneity in the enormous reserves of patient data stored in hospital data basis. Patterns in this data can tell us a lot about how a patient's cancer develops.
Sampling for most markers of cancer is performed on a too small fraction of a single block of tissue. Sample size plays a significant role in accurate cancer prognostics, especially when we take cancer heterogeneity into account.
Using prostate cancer as an example, the sample examined is a mere 1:1000 of a tumour. This small sample size means there is a higher risk of missing the cells that go on to kill the patient. Grading the sample and giving a correct prognosis depends heavily on the pathologist’s expertise. Pathologists assessing the same sample can arrive at vastly different results.
We have a team of national and international experts within many different fields, including digital image analysis, tumor pathology, cancer surgery and oncology.
The DoMore! project is funded by the Norwegian Research Council's ICT Lighthouse project grant